Last reviewed · How we verify
Steroid + cyclophosphamide
Steroids suppress immune inflammation while cyclophosphamide depletes proliferating immune cells, together inducing immunosuppression and potentially promoting immune tolerance.
Steroids suppress immune inflammation while cyclophosphamide depletes proliferating immune cells, together inducing immunosuppression and potentially promoting immune tolerance. Used for Autoimmune vasculitis, Severe systemic lupus erythematosus, ANCA-associated vasculitis.
At a glance
| Generic name | Steroid + cyclophosphamide |
|---|---|
| Sponsor | University Hospital, Rouen |
| Drug class | Immunosuppressive combination therapy |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Corticosteroids inhibit inflammatory cytokine production and immune cell activation. Cyclophosphamide is an alkylating agent that causes DNA cross-linking, leading to apoptosis of rapidly dividing cells including lymphocytes. The combination leverages both anti-inflammatory and cytotoxic mechanisms to suppress pathogenic immune responses, commonly used in autoimmune and vasculitic conditions.
Approved indications
- Autoimmune vasculitis
- Severe systemic lupus erythematosus
- ANCA-associated vasculitis
Common side effects
- Infection (opportunistic and bacterial)
- Hemorrhagic cystitis
- Myelosuppression
- Nausea and vomiting
- Secondary malignancy
- Infertility
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Steroid + cyclophosphamide CI brief — competitive landscape report
- Steroid + cyclophosphamide updates RSS · CI watch RSS
- University Hospital, Rouen portfolio CI